Atos and Huma, a digital health platform, have announced a 5-year strategic global partnership to shift healthcare and clinical trials from hospital to home. The partnership will focus on Huma’s modular platform which can power digital ‘hospitals at home’ up to national scale, as well as support pharmaceutical and research industries to run complex global decentralized clinical trials. The platform is already used in the US and across Europe for illnesses ranging from atrial fibrillation to diabetes to Covid-19.
Atos says that it will use its experience in implementing and scaling complex transformation projects to accelerate the adoption of Huma’s technology. This will include investment by Atos worth up to €20 million split across R&D and go-to-market resources, including dedicated consulting and sales personnel. The investment in R&D will fast-track the integration of the Huma platform with other leading clinical platforms, as well as develop a dedicated video module.
The companies add that the immense pressure exerted by the Covid-19 pandemic on the world’s healthcare systems exposed the weaknesses of current models already overstretched with ageing populations and the rising global incidence of chronic conditions. Atos and Huma’s approach aims for the scenario where patients are monitored outside of the hospital and given timely, proactive clinical intervention ahead of need, ultimately optimising the use of resources, improving patient outcomes and reducing long-term healthcare costs. Early-stage evidence has shown Huma’s service, which has already been operating nationally across Germany, England and the UAE can almost double hospital capacity, claims the company.
The 5-year partnership will begin with integration and enabling global go-to-market deployment.